SGLT2 Inhibitors & Kidney Disease: New Hope for IgA Nephropathy
Atrasentan, when added to standard care including SGLT2 inhibitors, demonstrates a statistically significant reduction in kidney failure risk for individuals with IgA nephropathy, according to findings from the pivotal ASSIST ... Read More